<DOC>
	<DOCNO>NCT02628210</DOCNO>
	<brief_summary>This single-arm post-market study patient require lumbar fusion use allograft interbody spacer conjunction map3® Cellular Allogeneic Bone Graft patient degenerative disc disease ( DDD ) . This cohort study enroll 80 patient total 10 site . After subject sign informed consent , baseline visit examination complete . Patients evaluate 6 week , 3 month , 6 month , 12 month , 24 month visit surgery .</brief_summary>
	<brief_title>Interbody Spacers With map3® Cellular Allogeneic Bone Graft Anterior Lateral Lumbar Interbody Fusion</brief_title>
	<detailed_description>Map3 allogeneic bone matrix also contain demineralized cortical cancellous bone multipotent adult progenitor cell ( MAPC ) . MAPC-based cell derive allograft bone marrow , isolated cell cryopreserved . Both scaffold cellular constituent process donor provide separate container . Scaffold cell combine constitute implant must use together . The map3 implant available Strips allograft Chips allograft configuration .</detailed_description>
	<mesh_term>Spondylolisthesis</mesh_term>
	<mesh_term>Intervertebral Disc Degeneration</mesh_term>
	<mesh_term>Spondylosis</mesh_term>
	<criteria>least 18 75 year age skeletally mature must symptomatic spondylosis , spondylolisthesis grade I II , degenerative disc disease ( DDD ) one level L2S1 require fusion must candidate use allograft spacer must candidate bilateral pedicle screw placement must complete minimum six week ( +/ two four week brace ) unsuccessful conservative , nonoperative care must discogenic back pain without leg pain DDD must confirm MRI CT scan follow discography ( necessary ) must score least 40 % Oswestry Disability Index must score 4 10 cm Visual Analog Scale back pain leg pain must able comply protocol 's followup schedule must understand sign inform consent documen symptomatic one level previous fusion surgery lumbar level without instrumentation . bone graft product study product local autograft bone . e.g . rhBMP2 , ( recombinant human bone morphogenetic protein 2 ) . patient require interbody fusion device allograft spacer ( Bigfoot™ , Crossfuse® Advantage ) . e.g . PEEK IBF 50 % spondylolisthesis ( Myerding grade III ) lumbar scoliosis great 11 degree osteoporosis* ( Tscore −2.5 low ) , osteomalacia , Paget 's disease metabolic bone disease . spinal tumor active arachnoiditis fracture epiphyseal plate fracture stabilization fracture possible . impaired calcium metabolism active infection surgical site infection rheumatoid arthritis autoimmune disease affect bone healing ( surgeon 's discretion ) chronic steroid use except chronic inhaler ( use steroid one month within last 6 month ) medical condition require treatment drug know interfere bone healing use glucocorticoid &gt; 10 mg/day systemic disease AIDS , HIV , hepatitis ( active ) , tuberculosis morbid obesity define body mass index ( BMI ) &gt; 45 weight 100 lb . ideal body weight uncontrolled diabetes document Hbg A1C &gt; 9 insulin dependent diabetic smoker unless approve Sponsor , include electronic cigarette vaporizer within past two ( 2 ) year , psychosocial disorder would preclude accurate evaluation history substance abuse history active cancer pregnancy , interested become pregnant participate study participation another investigational study within 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>